Nymox Pursuing New Approaches to an Old Disease
One such program targets spherons, tiny balls of densely packed protein found in the human brain and believed by Nymox scientists to be a major cause of senile plaques. Senile plaques are found abundantly in the brains of patients with Alzheimer's disease and are believed by many researchers to play a pivotal role in the fatal illness. Nymox has used spheron-based drug screening methods to discover, develop and test unique drug candidates aimed at limiting the formation of Alzheimer plaques from spherons and thus slowing or stopping the progression of the disease.
Another Nymox AD program targets neural thread protein (NTP), the brain protein measured by AlzheimAlert(TM), the Company's urine based diagnostic aid for AD. AlzheimAlert(TM) is currently available in Europe as a kit with the CE Mark and in the US as a CLIA certified clinical reference laboratory test service. Nymox has developed new drug candidates designed to inhibit the effects of over-production of NTP in the AD brain.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.